VK2735

VK2735 is an investigational dual GIP/GLP-1 receptor agonist from Viking Therapeutics that produced substantial weight loss in a 13-week Phase 2 injection trial. VK2735 is not FDA-approved, long-term Phase 3 results are unavailable, and gray-market VK2735 is not the clinical-trial product—even when a seller borrows the study’s dosage numbers.

Key facts

• What it is: a synthetic peptide that activates the GLP-1 and GIP receptors
• Studied for: weight management in adults with obesity or overweight
• Evidence tier: human randomized trial, but Phase 2 and short-term
• U.S. status: investigational as of July 16, 2026; no approved use
• Doses studied: 2.5–15 mg weekly by injection; 15–120 mg daily orally
• Main known risks: nausea, constipation, vomiting, diarrhea, and unknown long-term safety
• Sport: prohibited at all times under WADA’s S0 non-approved-substances rule

What is VK2735?

VK2735 is Viking Therapeutics’ experimental weight-management peptide, built to activate the same two incretin receptors targeted by tirzepatide: GLP-1 and GIP. The injectable form is taken weekly in trials; a separate VK2735 oral tablet is being developed for daily dosing. Neither form is an approved medicine.

The VK2735 peptide has no verified public PubChem identifier or CAS number. Vendor catalogs may publish confident-looking chemistry fields, but an empty identifier is better than telling readers that VK2735 is the wrong molecule.

How does VK2735 work?

VK2735 activates two receptors involved in the body’s response to food. GLP-1 signaling reduces appetite and supports glucose-dependent insulin release; GIP signaling adds another meal-linked insulin and satiety signal. Think of VK2735 as turning up two parts of the after-meal message instead of one.

That mechanism makes Viking Therapeutics’ VK2735 a dual agonist, not simply another single-target GLP-1 peptide. Receptor activity explains why weight loss is plausible. It does not establish how VK2735 performs over years or compares with an approved drug.

What does the VK2735 weight loss evidence show?

VK2735 produced dose-related weight loss over 13 weeks in the randomized, double-blind, placebo-controlled VENTURE trial. Among 176 randomized adults without diabetes, mean weight reduction ranged from 9.1% with 2.5 mg weekly to 14.7% with 15 mg weekly, versus 1.7% with placebo. That is a strong Phase 2 signal, not a finished verdict.

The published VENTURE paper also reports that 130 of 140 participants receiving VK2735 lost at least 5% of baseline weight, compared with 4 of 34 on placebo. The study excluded people with diabetes and was funded by Viking; its authors were trial-site investigators or company employees. Phase 2 found a real effect. Phase 3 must show how much survives a longer test.

What did the VK2735 oral trial find?

VK2735 oral tablets also produced dose-related weight loss in a randomized 13-week Phase 2 study, but the detailed result currently lives in a conference poster rather than a full peer-reviewed paper. The highest 120 mg daily arm lost 12.2% of baseline weight, while placebo lost 1.3%; doses above 15 mg beat placebo statistically.

The VENTURE-Oral registry records 280 enrolled participants, while the ECO 2026 poster presents six placebo or dose cohorts of 40 people for its main comparison. The honest grade is human RCT, Phase 2, conference-level reporting. A poster can be useful evidence; it is not a substitute for the full paper.

Is the VK2735 peptide safe?

VK2735’s short-term safety picture is mostly gastrointestinal, while its long-term safety remains unknown. In VENTURE, nausea, constipation, vomiting, and diarrhea were the recurring adverse events. Most were mild or moderate, but 7 of 35 people assigned to the 15 mg dose stopped treatment early because of an adverse event, versus none of 35 on placebo.

Thirteen weeks cannot settle uncommon harms, pregnancy risk, or outcomes after years of use. VK2735 has no FDA prescribing information, so copying contraindications from tirzepatide would be guesswork. Gray-market vials add a different risk layer: the label cannot prove identity, concentration, purity, sterility, or cold-chain handling. The gray-market peptide guide explains why a vendor assay is not the quality system used in a clinical trial.

What was the VK2735 dosage in studies?

VK2735 dosage has been tested as weekly injections of 2.5, 5, 10, or 15 mg in VENTURE, with dose titration, and as daily oral doses from 15 to 120 mg in VENTURE-Oral. These are research arms used to compare groups—not a personal schedule and not instructions for a gray-market vial.

The active Phase 3 injection studies use 7.5, 12.5, and 17.5 mg once weekly against placebo. Those doses belong to monitored protocols with eligibility rules, titration, laboratory checks, and defined follow-up. Removing the protocol and keeping only the milligram number is not “following the study.” It is keeping the easiest line and discarding the safety machinery around it.

Is VK2735 FDA-approved or legal in 2026?

VK2735 is investigational and not FDA-approved in the United States as of July 16, 2026. VANQUISH-1 and VANQUISH-2 are both listed as Phase 3, active, and not recruiting on ClinicalTrials.gov; neither has posted results. There is no approved VK2735 indication, brand, label, or standard retail prescription product.

VANQUISH-1 plans to follow about 4,500 adults without type 2 diabetes for 78 weeks. VANQUISH-2 plans about 1,100 adults with type 2 diabetes for 78 weeks. The FDA warns that unapproved GLP-1 products sold online may have the wrong ingredient or amount and specifically warns about products falsely labeled for research. An online checkout does not turn trial access into pharmacy access.

WADA’s 2026 list also puts drugs in clinical development without human therapeutic approval under S0, prohibited at all times. Competitive athletes should treat VK2735 as banned, even though the list does not need to name every investigational code individually.

VK2735 vs retatrutide: which has better evidence?

VK2735 vs retatrutide cannot be decided from a direct trial because no head-to-head study has compared them. VK2735 activates GLP-1 and GIP; retatrutide adds a glucagon-receptor action. Both have randomized human weight-loss data, but their trials used different doses, durations, and populations, so lining up the largest percentages creates a race the studies never ran.

Tirzepatide is the cleaner mechanism comparison because it is also a dual GIP/GLP-1 agonist—and, unlike VK2735, it is FDA-approved. The real test is whether 78-week VANQUISH results preserve the effect with acceptable discontinuation and safety rates. Until then, the accurate label is promising Phase 2 drug, not next-generation winner.